| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 Narcolepsy Type 2 | Phase 3 | 2026-04-01 |
| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 Narcolepsy Type 1 | Phase 3 | 2026-03-01 |
| Recruiting | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia Idiopathic Hypersomnia | Phase 2 | 2025-05-22 |
| Recruiting | A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia | Phase 2 / Phase 3 | 2025-01-27 |
| Completed | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 Narcolepsy Type 2 | Phase 2 | 2024-07-26 |
| Completed | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-20 Narcolepsy Type 1 | Phase 2 | 2024-03-28 |
| Completed | Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan Focus of Study is on Healthy Lactating Women | Phase 1 | 2022-09-14 |
| Recruiting | Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Schizophrenia, Bipolar I Disorder | Phase 3 | 2022-06-30 |
| Enrolling By Invitation | Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects Bipolar I Disorder, Schizophrenia | Phase 3 | 2021-10-22 |
| Terminated | Phase 1 ALKS 1140 in Healthy Adults Central Nervous System Diseases | Phase 1 | 2021-10-13 |
| Completed | Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder Bipolar I Disorder | Phase 1 | 2021-07-22 |
| Terminated | A 28 Day Parallel Group Study to Assess the Effects of RDN-929 Healthy | Phase 1 | 2019-05-16 |
| Completed | Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS) Schizophrenia | — | 2019-03-28 |
| Completed | Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects Healthy | Phase 1 | 2018-10-10 |
| Terminated | A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) Refractory Major Depressive Disorder | Phase 3 | 2018-08-09 |
| Completed | A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density Healthy, Alzheimer Disease | EARLY_Phase 1 | 2018-07-23 |
| Completed | A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia Schizophrenia | Phase 3 | 2017-11-15 |
| Completed | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 Schizophrenia, Schizophreniform Disorder, Bipolar I Disorder | Phase 3 | 2017-06-15 |
| Completed | A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD) Major Depressive Disorder | Phase 3 | 2017-06-12 |
| Completed | Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed Wi Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder | Phase 3 | 2017-06-08 |
| Completed | An Insulin Sensitivity Study in Healthy Subjects Healthy Volunteers | Phase 1 | 2016-09-01 |
| Completed | A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia Schizophrenia | Phase 3 | 2016-08-07 |
| Completed | A Phase 1 Safety Study in Adults With Schizophrenia Schizophrenia | Phase 1 | 2016-06-01 |
| Completed | Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioni Opioid Use Disorder | Phase 3 | 2016-04-01 |
| Completed | A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study) Schizophrenia | Phase 3 | 2016-03-02 |
| Completed | A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia Schizophrenia | Phase 3 | 2016-01-20 |
| Completed | A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study) Schizophrenia | Phase 3 | 2015-12-01 |
| Completed | A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder Schizophrenia, Schizoaffective Disorder | Phase 1 | 2015-12-01 |
| Completed | A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia Schizophrenia | Phase 4 | 2015-12-01 |
| Completed | Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of Opioid Use Disorder | Phase 3 | 2015-08-01 |
| Completed | A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers Healthy Volunteers | Phase 1 | 2015-07-01 |
| Completed | Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function Renal Impairment | Phase 1 | 2015-07-01 |
| Completed | A Water Consumption Study of ALKS 5461 in Healthy Volunteers Healthy | Phase 1 | 2015-07-01 |
| Completed | A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers Healthy | Phase 1 | 2015-06-01 |
| Completed | A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers Healthy | Phase 1 | 2015-06-01 |
| Completed | Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal H Hepatic Impairment | Phase 1 | 2015-05-01 |
| Completed | A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users Healthy | Phase 1 | 2015-03-01 |
| Completed | An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia Schizophrenia | Phase 1 | 2014-12-01 |
| Completed | A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers Pharmacokinetics | Phase 1 | 2014-10-01 |
| Completed | A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users Healthy Volunteers | Phase 1 | 2014-08-01 |
| Completed | A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study Major Depressive Disorder | Phase 3 | 2014-07-01 |
| Completed | A Long-Term Safety Study of ALKS 5461 Major Depressive Disorder | Phase 3 | 2014-05-01 |
| Completed | A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study Major Depressive Disorder | Phase 3 | 2014-05-01 |
| Completed | A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study Major Depressive Disorder | Phase 3 | 2014-05-01 |
| Completed | A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder Schizophrenia, Alcohol Use Disorder | Phase 2 | 2014-05-01 |
| Completed | A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD) Major Depressive Disorder | Phase 3 | 2014-02-01 |
| Completed | A Study of ALKS 5461 in Healthy Volunteers Pharmacokinetics | Phase 1 | 2014-01-01 |
| Completed | An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) Schizophrenia | Phase 3 | 2013-07-01 |
| Completed | A Study of ALKS 3831 in Adults With Schizophrenia Schizophrenia | Phase 2 | 2013-06-01 |
| Completed | A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) Schizophrenia | Phase 3 | 2012-06-01 |
| Completed | A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD) Major Depressive Disorder | Phase 2 | 2011-12-01 |
| Completed | A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia Schizophrenia | Phase 1 | 2011-12-01 |
| Completed | A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or A Schizophrenia | Phase 3 | 2011-12-01 |
| Terminated | Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery Laparoscopic Surgery | Phase 3 | 2011-10-01 |
| Completed | ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation OIC | Phase 2 | 2011-09-01 |
| Completed | ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered Wi Cocaine Abuse | Phase 1 | 2011-08-01 |
| Completed | ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC) Opioid-induced Constipation | Phase 2 | 2011-08-01 |
| Completed | ALK21-025: Vivitrol's Cost and Treatment Outcomes Registry Opioid Dependence | — | 2011-08-01 |
| Completed | ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD Major Depressive Disorder | Phase 1 / Phase 2 | 2011-05-01 |
| Completed | A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Opioid Dependence | Phase 4 | 2011-01-01 |
| Completed | ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder Binge Eating Disorder | Phase 2 | 2010-05-01 |
| Completed | ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC) Opioid-induced Constipation | Phase 2 | 2010-04-01 |
| Completed | Study to Evaluate the Efficacy, Safety and Tolerability of N1539 Hysterectomy | Phase 2 | 2010-03-01 |
| Completed | ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence Alcohol Dependence | Phase 2 | 2009-10-01 |
| Completed | Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery Dental Pain | Phase 2 | 2009-07-01 |
| Completed | ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals Opiate Dependence | Phase 3 | 2009-03-01 |
| Completed | ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | 2009-02-01 |
| Completed | ALK33-001: A Study of RDC-0313 Administered to Healthy Adults Alcohol Dependence | Phase 1 | 2008-12-01 |
| Completed | ALK29-002: A Study of Baclofen Formulations in Healthy Adults Alcohol Dependence | Phase 1 | 2008-11-01 |
| Completed | ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence Opiate Dependence | Phase 3 | 2008-06-01 |
| Completed | ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-depend Alcohol Dependence | Phase 4 | 2007-07-01 |
| Completed | ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence Alcohol Dependence | Phase 3 | 2007-07-01 |
| Terminated | ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Ext Alcoholism, Opiate Dependence | Phase 3 | 2004-08-01 |
| Completed | ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults Alcoholism | Phase 3 | 2003-10-01 |
| Completed | ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®) Alcoholism | Phase 3 | 2003-08-01 |
| Completed | ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexo Alcohol Dependence | Phase 3 | 2002-08-01 |
| Completed | ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids Opiate Dependence | Phase 2 | 2002-03-01 |
| Completed | ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults Alcoholism | Phase 3 | 2002-02-01 |
| Completed | The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis Meningitis, Cryptococcal, HIV Infections | Phase 1 | — |